期刊
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
卷 6, 期 6, 页码 535-545出版社
ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
DOI: 10.22608/APO.2017350
关键词
diabetic retinopathy; diabetic macular edema; vascular endothelial growth factor
Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the working-age population. The identification of vascular endothelial growth factor (VEGF) as a key mediator in the pathogenesis of DR has revolutionized the management of this vision-threatening disease. There is now strong evidence supporting intravitreal anti-VEGF therapy as first line in the management of sight-threatening diabetic macular edema (DME), along with a growing body of evidence to support the use of anti-VEGF drugs for proliferative DR. This review summarizes the role of VEGF in DR, the evidence for anti-VEGF therapy, safety considerations, and the future of anti-VEGF therapy for the management of DR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据